Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson’s (NYSE:JNJ) popular biologic drug used to treat autoimmune diseases when obtained through pharmacies rather ...
South Korean biosimilars specialist Celltrion said the European medicines regulator has adopted a positive opinion for an autoinjector version of SteQeyma, its biosimilar to Stelara (ustekinumab).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback